Sentence examples for development of orphans from inspiring English sources

Recommendations Zimbabwe should strengthen the provision of basic services, since these services are key to the survival and development of orphans and other vulnerable children.

Nevertheless, this analysis offers new insight into the relationship between psychosocial factors, exposure to adverse childhood experiences, resource constraints and the cognitive development of orphans in wide variety of contexts and diverse settings in Southeast Asia and sub-Saharan Africa.

The authors' opinion article indicates one of the great barriers to the development of orphan products has been the financial risk of developing a product for a disease with very small patient populations of potential users.

To this end, a robust, small sample, exploratory analysis of Dutch multi-actor development of orphan drugs was performed.

These medical conditions are normally referred to as rare diseases and there is much current interest in the development of orphan drugs for the treatment of such diseases [2 4].

The EU provides a range of incentives to encourage the development of orphan drugs, the most important of which is a high level of market exclusivity: once a medicine has been awarded an orphan drug authorisation by the European Commission, no similar medicinal product can be brought to the European market for a period of ten years.

The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs (i.e., medicinal products that are designed to treat rare disease that affect only small numbers of patients).

Regulations create special incentives for the development of orphan drugs to encourage new treatments for rare conditions, but public policy has largely neglected the issue of massive price increases for these drugs once they are no longer new.

Recent literature has discussed factors that influenced the development of orphan medicinal products in Europe [ 12, 14, 19].

Thus, there remains a need for regulatory incentives that promote investment for research and development of orphan drugs.

Karen A. McDonald is a co-founder of Inserogen, Inc., a plant-based biotechnology company with a focus on the development of orphan drugs for replacement therapy.